NYSE:PBH - Prestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare Inc (NYSE:PBH) announced its quarterly earnings data on Thursday, October, 31st. The company reported $0.68 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.02. The company earned $238.07 million during the quarter, compared to analyst estimates of $237.17 million. Prestige Consumer Healthcare had a negative net margin of 3.56% and a positive return on equity of 12.68%. The firm's revenue for the quarter was down .5% on a year-over-year basis. During the same quarter last year, the business posted $0.65 EPS. View Prestige Consumer Healthcare's Earnings History.

Prestige Consumer Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Prestige Consumer Healthcare.

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Prestige Consumer Healthcare updated its FY20 earnings guidance on Thursday, October, 31st. The company provided EPS guidance of $2.76-2.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.82. The company issued revenue guidance of $947-957 million, compared to the consensus revenue estimate of $953.18 million.

3 brokerages have issued 12-month price objectives for Prestige Consumer Healthcare's stock. Their forecasts range from $84.00 to $97.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $89.67 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price. View Analyst Price Targets for Prestige Consumer Healthcare.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prestige Consumer Healthcare.

News articles about PBH stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Prestige Consumer Healthcare.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), USANA Health Sciences (USNA), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Cara Therapeutics (CARA), IQIYI (IQ), Rigel Pharmaceuticals (RIGL), AbbVie (ABBV), Boeing (BA), Edwards Lifesciences (EW), Johnson & Johnson (JNJ) and AT&T (T).

Prestige Consumer Healthcare's stock is owned by a number of of retail and institutional investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (0.69%), Wedge Capital Management L L P NC (0.43%), Skyline Asset Management LP (0.37%), Peregrine Capital Management LLC (0.37%), Nisa Investment Advisors LLC (0.05%) and OLD National Bancorp IN (0.02%). Company insiders that own Prestige Consumer Healthcare stock include Gary E Costley, Jean A Boyko, Natale S Ricciardi, Paton Brett, Ronald M Lombardi, Timothy Connors and William P'pool. View Institutional Ownership Trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Skyline Asset Management LP, Dalton Greiner Hartman Maher & Co. and State of Alaska Department of Revenue. View Insider Buying and Selling for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Peregrine Capital Management LLC, Diversified Trust Co, OLD National Bancorp IN and Nisa Investment Advisors LLC. Company insiders that have bought Prestige Consumer Healthcare stock in the last two years include Gary E Costley, Natale S Ricciardi, Ronald M Lombardi and William P'pool. View Insider Buying and Selling for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $42.20.

Prestige Consumer Healthcare has a market capitalization of $2.12 billion and generates $975.78 million in revenue each year. The company earns $-35,800,000.00 in net income (profit) each year or $2.78 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.View Additional Information About Prestige Consumer Healthcare.

The official website for Prestige Consumer Healthcare is http://www.prestigebrands.com/.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]